This Elrexfio market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the rise in patient registries, increased government investments in oncology, a growing prevalence of hematologic malignancies, heightened patient awareness and advocacy, and rising investments in research and development.
Growth during the forecast period can be attributed to the development of bispecific antibodies, expansion in emerging markets, increased investment in oncology research, an expanding pipeline of BCMA-targeted therapies, and advancements in diagnostic tools. Key trends in the forecast period include progress in protein engineering, integration of oncology treatment pathways, the adoption of telemedicine, a shift from chemotherapy to targeted therapies, and the incorporation of artificial intelligence in drug development.
The increasing prevalence of multiple myeloma is anticipated to drive the growth of the elrexfio market in the coming years. Multiple myeloma is a cancer that develops in plasma cells, a type of white blood cell located in the bone marrow. It results in the abnormal growth and accumulation of these cells, causing damage to bones, kidneys, and other organs. Factors contributing to the prevalence of multiple myeloma include an aging population, increased awareness, advancements in diagnostic techniques, and improved healthcare access that facilitates better disease detection. Elrexfio (elranatamab) is a monoclonal antibody designed to treat multiple myeloma by targeting and binding to the BCMA (B-cell maturation antigen) protein on the surface of myeloma cells, thereby activating the immune system to destroy these cancer cells. For instance, in February 2023, Cancer Research UK, a UK-based research organization, projected that the annual number of new myeloma cases in the UK would rise from approximately 6,800 cases between 2023-2025 to around 8,300 between 2038-2040. As a result, the increasing prevalence of multiple myeloma is driving the growth of the elrexfio market.
The rise in research and clinical trials is expected to further propel the growth of the elrexfio market in the future. Research and clinical trials involve systematic studies to assess new medical tests, treatments, and interventions for their safety and effectiveness in improving health outcomes. The surge in research and clinical trials is primarily driven by advancements in medical technology, the growing prevalence of chronic diseases, and the demand for innovative treatments. Elrexfio contributes to this progress by offering a highly effective treatment option for relapsed or refractory multiple myeloma, potentially reducing the need for additional experimental therapies. For example, in November 2023, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported a 4.3% increase in the annual number of industry clinical trials in the UK, rising from 394 trials in 2021 to 411 in 2022. Consequently, the rise in research and clinical trials will drive the growth of the elrexfio market.
The key trend in the elrexfio market is focusing on developing advanced therapies, such as B-cell maturation antigen-targeted treatments, to enhance the efficacy of treatments for cancer and autoimmune diseases. BCMA-targeted therapy is a cancer treatment designed to target the BCMA protein on the surface of malignant plasma cells, such as those present in multiple myeloma. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for elranatamab-bcmm (Elrexfio). Elranatamab-bcmm (Elrexfio) is a bispecific T-cell engager therapy that targets BCMA on multiple myeloma cells and CD3 on T-cells, enabling the immune system to combat relapsed or refractory multiple myeloma in adults who have received several prior treatments.
The key company operating in the elrexfio market is Pfizer Inc.
North America was the largest region in the elrexfio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elrexfio report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elrexfio market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elrexfio is the brand name for epcoritamab, a monoclonal antibody designed for the treatment of relapsed or refractory B-cell malignancies, particularly B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab works by targeting and eliminating cancerous B-cells through its dual engagement of CD3 on T-cells and CD20 on B-cells.
The primary indications for elrexfio include multiple myeloma and other hematologic cancers. Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to immune dysfunction, bone damage, and organ impairment. This condition can be treated with therapies such as Elrexfio, which targets BCMA. Elrexfio is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is utilized by a range of end users, such as hospitals, specialty clinics, research institutions, and others.
The elrexfio market research report is one of a series of new reports that provides elrexfio market statistics, including the elrexfio industry global market size, regional shares, competitors with the elrexfio market share, detailed elrexfio market segments, market trends, and opportunities, and any further data you may need to thrive in the elrexfio industry. This elrexfio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The elrexfio market consists of sales of combination therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the rise in patient registries, increased government investments in oncology, a growing prevalence of hematologic malignancies, heightened patient awareness and advocacy, and rising investments in research and development.
Growth during the forecast period can be attributed to the development of bispecific antibodies, expansion in emerging markets, increased investment in oncology research, an expanding pipeline of BCMA-targeted therapies, and advancements in diagnostic tools. Key trends in the forecast period include progress in protein engineering, integration of oncology treatment pathways, the adoption of telemedicine, a shift from chemotherapy to targeted therapies, and the incorporation of artificial intelligence in drug development.
The increasing prevalence of multiple myeloma is anticipated to drive the growth of the elrexfio market in the coming years. Multiple myeloma is a cancer that develops in plasma cells, a type of white blood cell located in the bone marrow. It results in the abnormal growth and accumulation of these cells, causing damage to bones, kidneys, and other organs. Factors contributing to the prevalence of multiple myeloma include an aging population, increased awareness, advancements in diagnostic techniques, and improved healthcare access that facilitates better disease detection. Elrexfio (elranatamab) is a monoclonal antibody designed to treat multiple myeloma by targeting and binding to the BCMA (B-cell maturation antigen) protein on the surface of myeloma cells, thereby activating the immune system to destroy these cancer cells. For instance, in February 2023, Cancer Research UK, a UK-based research organization, projected that the annual number of new myeloma cases in the UK would rise from approximately 6,800 cases between 2023-2025 to around 8,300 between 2038-2040. As a result, the increasing prevalence of multiple myeloma is driving the growth of the elrexfio market.
The rise in research and clinical trials is expected to further propel the growth of the elrexfio market in the future. Research and clinical trials involve systematic studies to assess new medical tests, treatments, and interventions for their safety and effectiveness in improving health outcomes. The surge in research and clinical trials is primarily driven by advancements in medical technology, the growing prevalence of chronic diseases, and the demand for innovative treatments. Elrexfio contributes to this progress by offering a highly effective treatment option for relapsed or refractory multiple myeloma, potentially reducing the need for additional experimental therapies. For example, in November 2023, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported a 4.3% increase in the annual number of industry clinical trials in the UK, rising from 394 trials in 2021 to 411 in 2022. Consequently, the rise in research and clinical trials will drive the growth of the elrexfio market.
The key trend in the elrexfio market is focusing on developing advanced therapies, such as B-cell maturation antigen-targeted treatments, to enhance the efficacy of treatments for cancer and autoimmune diseases. BCMA-targeted therapy is a cancer treatment designed to target the BCMA protein on the surface of malignant plasma cells, such as those present in multiple myeloma. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for elranatamab-bcmm (Elrexfio). Elranatamab-bcmm (Elrexfio) is a bispecific T-cell engager therapy that targets BCMA on multiple myeloma cells and CD3 on T-cells, enabling the immune system to combat relapsed or refractory multiple myeloma in adults who have received several prior treatments.
The key company operating in the elrexfio market is Pfizer Inc.
North America was the largest region in the elrexfio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elrexfio report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elrexfio market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elrexfio is the brand name for epcoritamab, a monoclonal antibody designed for the treatment of relapsed or refractory B-cell malignancies, particularly B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab works by targeting and eliminating cancerous B-cells through its dual engagement of CD3 on T-cells and CD20 on B-cells.
The primary indications for elrexfio include multiple myeloma and other hematologic cancers. Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to immune dysfunction, bone damage, and organ impairment. This condition can be treated with therapies such as Elrexfio, which targets BCMA. Elrexfio is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is utilized by a range of end users, such as hospitals, specialty clinics, research institutions, and others.
The elrexfio market research report is one of a series of new reports that provides elrexfio market statistics, including the elrexfio industry global market size, regional shares, competitors with the elrexfio market share, detailed elrexfio market segments, market trends, and opportunities, and any further data you may need to thrive in the elrexfio industry. This elrexfio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The elrexfio market consists of sales of combination therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Elrexfio Market Characteristics4. Elrexfio Market Trends and Strategies5. Elrexfio Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Elrexfio Pricing Analysis & Forecasts30. Global Elrexfio Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Elrexfio Market32. Recent Developments in the Elrexfio Market
3. Elrexfio Market Biologic Drug Characteristics
6. Global Elrexfio Growth Analysis and Strategic Analysis Framework
8. Elrexfio Market Segmentation
9. Global Elrexfio Epidemiology of Clinical Indications
10. Elrexfio Market Regional and Country Analysis
11. Asia-Pacific Elrexfio Market
12. China Elrexfio Market
13. India Elrexfio Market
14. Japan Elrexfio Market
15. Australia Elrexfio Market
16. South Korea Elrexfio Market
17. Western Europe Elrexfio Market
18. UK Elrexfio Market
19. Germany Elrexfio Market
20. France Elrexfio Market
21. Eastern Europe Elrexfio Market
22. North America Elrexfio Market
23. USA Elrexfio Market
24. Canada Elrexfio Market
25. South America Elrexfio Market
26. Middle East Elrexfio Market
27. Africa Elrexfio Market
28. Elrexfio Market Competitive Landscape and Company Profiles
29. Global Elrexfio Market Pipeline Analysis
33. Elrexfio Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Elrexfio Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on elrexfio market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for elrexfio? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The elrexfio market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Multiple Myeloma; Other Hematologic Cancers2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) by End User: Hospitals; Specialty Clinics; Research Institutions; Other End Users
Key Companies Mentioned:Pfizer Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
